Long non-coding RNAs: The hidden players in diabetes mellitus-related complications

Hussein, Rasha M.

doi:10.1016/j.dsx.2023.102872

Cited by 8 publications

(8 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our group and others have already described the critical role of lncRNA H19 in atherosclerosis and aneurysm 61 – 63 . Furthermore, H19 has long been proven to be connected with the phenotypic switch of SMCs 64 and diabetes, especially in the regulation of glucose metabolism 65 , 66 . In our experimental setup, H19 was involved in the binding of RNA by insulin-like growth factor 2 mRNA binding proteins (IGF2BPs).…”

Section: Discussionmentioning

confidence: 99%

“…Regarding the gene set enrichment analysis, H19 seemed to be involved again, together with NEAT1, CARMN, MIR23AHG, MIR29B2CHG, MIR663AHG, MIRLET7A1HG, LINC-PINT, FTX , and MEG3 . Of these lncRNAs, irrespective of the already described NEAT1, MIR29B2CHG , and H19 , the lncRNA CARMN and MEG3 have already been described in the context of CVDs and SMCs 40 , 66 , 70 – 73 . The lncRNA CARMN has been associated with atherosclerosis 40 , 72 and SMC plasticity 70 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Transcriptomics analysis of long non-coding RNAs in smooth muscle cells from patients with peripheral artery disease and diabetes mellitus

Yundung,

Mohammed,

Paneni

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a significant risk factor for peripheral arterial disease (PAD), and PAD is an independent predictor of cardiovascular disorders (CVDs). Growing evidence suggests that long non-coding RNAs (lncRNAs) significantly contribute to disease development and underlying complications, particularly affecting smooth muscle cells (SMCs). So far, no study has focused on transcriptome analysis of lncRNAs in PAD patients with and without DM. Tissue samples were obtained from our Vascular Biobank. Due to the sample’s heterogeneity, expression analysis of lncRNAs in whole tissue detected only ACTA2-AS1 with a 4.9-fold increase in PAD patients with DM. In contrast, transcriptomics of SMCs revealed 28 lncRNAs significantly differentially expressed between PAD with and without DM (FDR < 0.1). Sixteen lncRNAs were of unknown function, six were described in cancer, one connected with macrophages polarisation, and four were associated with CVDs, mainly with SMC function and phenotypic switch (NEAT1, MIR100HG, HIF1A-AS3, and MRI29B2CHG). The enrichment analysis detected additional lncRNAs H19, CARMN, FTX, and MEG3 linked with DM. Our study revealed several lncRNAs in diabetic PAD patients associated with the physiological function of SMCs. These lncRNAs might serve as potential therapeutic targets to improve the function of SMCs within the diseased tissue and, thus, the clinical outcome.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Transcriptomics analysis of long non-coding RNAs in smooth muscle cells from patients with peripheral artery disease and diabetes mellitus

Yundung,

Mohammed,

Paneni

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The regulation of numerous pathophysiological processes associated with glomerular Mesangial cells (MCs), podocytes, and tubular epithelial cells can be attributed to lncRNAs. These processes include but are not limited to cell proliferation, apoptosis and autophagy, extracellular matrix (ECM) accumulation, oxidative stress, endoplasmic reticulum stress (ERS), mitochondrial dysfunction, inflammatory response, epithelial‐mesenchymal transition (EMT), and fibrosis 15 . In particular, the lncRNA‐miRNA regulatory network also plays an important role in the pathologic changes of DKD.…”

Section: Long Non‐coding Rnamentioning

confidence: 99%

“…These changes lead to typical clinical features like persistent proteinuria and a progressive decline in renal function and eventually to the development of ESKD 14 . Furthermore, the body of research indicates that long non‐coding RNAs (lncRNAs) are strongly related to the onset and progression of DKD and are crucial in controlling several molecular pathways involved in the pathogenesis of DKD, and are also novel biomarkers and potential therapeutic targets 15 …”

Section: Introductionmentioning

confidence: 99%

“…14 Furthermore, the body of research indicates that long non-coding RNAs (lncRNAs) are strongly related to the onset and progression of DKD and are crucial in controlling several molecular pathways involved in the pathogenesis of DKD, and are also novel biomarkers and potential therapeutic targets. 15 Therefore, we include an overview of recent developments involving the mechanism of pathological and structural alterations in DKD regulated by lncRNAs in various in vivo and in vitro models as well as in human studies in this review and also summarise the potential of lncRNAs as diagnostic biomarkers and targets for therapeutic intervention in DKD.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The role of long non‐coding RNAs in the development of diabetic kidney disease and the involved clinical application

Hou,

2024

Diabetes Metabolism Res

View full text Add to dashboard Cite

Diabetic kidney disease (DKD), one of the common microvascular complications of diabetes, is increasing in prevalence worldwide and can lead to End‐stage renal disease. However, there are still gaps in our understanding of the pathophysiology of DKD, and both current clinical diagnostic methods and treatment strategies have drawbacks. According to recent research, long non‐coding RNAs (lncRNAs) are intimately linked to the developmental process of DKD and could be viable targets for clinical diagnostic decisions and therapeutic interventions. Here, we review recent insights gained into lncRNAs in pathological changes of DKD such as mesangial expansion, podocyte injury, renal tubular injury, and interstitial fibrosis. We also discuss the clinical applications of DKD‐associated lncRNAs as diagnostic biomarkers and therapeutic targets, as well as their limitations and challenges, to provide new methods for the prevention, diagnosis, and treatment of DKD.

show abstract

Therapeutic potential of natural antisense transcripts and various mechanisms involved for clinical applications and disease prevention

Ali,

Khatoon,

Shao

et al. 2023

RNA Biology

View full text Add to dashboard Cite

Antisense transcription, a prevalent occurrence in mammalian genomes, gives rise to natural antisense transcripts (NATs) as RNA molecules. These NATs serve as agents of diverse transcriptional and post-transcriptional regulatory mechanisms, playing crucial roles in various biological processes vital for cell function and immune response. However, when their normal functions are disrupted, they can contribute to human diseases. This comprehensive review aims to establish the molecular foundation linking NATs to the development of disorders like cancer, neurodegenerative conditions, and cardiovascular ailments. Additionally, we evaluate the potential of oligonucleotide-based therapies targeting NATs, presenting both their advantages and limitations, while also highlighting the latest advancements in this promising realm of clinical investigation. Abbreviations: NATs- Natural antisense transcripts, PRC1- Polycomb Repressive Complex 1, PRC2- Polycomb Repressive Complex 2, ADARs- Adenosine deaminases acting on RNA, BDNF-AS- Brain-derived neurotrophic factor antisense transcript, ASOs- Antisense oligonucleotides, SINEUPs- Inverted SINEB2 sequence-mediated upregulating molecules, PTBP1- Polypyrimidine tract binding protein-1, HNRNPK- heterogeneous nuclear ribonucleoprotein K, MAPT-AS1- microtubule-associated protein tau antisense 1, KCNQ1OT- (KCNQ1 opposite strand/antisense transcript 1, ERK- extracellular signal-regulated kinase 1, USP14- ubiquitin-specific protease 14, EGF- Epidermal growth factor, LSD1- Lysine Specific Demethylase 1, ANRIL- Antisense Noncoding RNA in the INK4 Locus, BWS- Beckwith-Wiedemann syndrome, VEGFA- Vascular Endothelial Growth component A

show abstract

Long non-coding RNAs: The hidden players in diabetes mellitus-related complications

Cited by 8 publications

References 81 publications

Transcriptomics analysis of long non-coding RNAs in smooth muscle cells from patients with peripheral artery disease and diabetes mellitus

Transcriptomics analysis of long non-coding RNAs in smooth muscle cells from patients with peripheral artery disease and diabetes mellitus

The role of long non‐coding RNAs in the development of diabetic kidney disease and the involved clinical application

Therapeutic potential of natural antisense transcripts and various mechanisms involved for clinical applications and disease prevention

Contact Info

Product

Resources

About